Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metabolically armed tumor-infiltrating lymphocytes
- Development stage
- Phase 2
- Lead developer
- Leman Biotech
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Metabolically armed tumor-infiltrating lymphocytes (Meta10-TIL) is an autologous cell therapy consisting of T cells harvested from a patient's tumor that have been expanded ex vivo and metabolically reprogrammed to enhance their fitness and anti-tumor activity. Developed by researchers at The First Affiliated Hospital of USTC (Anhui Provincial Hospital), this therapy addresses a primary limitation of conventional TIL therapies: the rapid exhaustion and loss of function of T cells within the nutrient-depleted and immunosuppressive tumor microenvironment (TME). The 'Meta10' platform involves optimizing the metabolic profile of the TILs—potentially through genetic modification or specific culture conditions—to ensure they maintain high mitochondrial mass and efficient nutrient uptake upon re-infusion. This metabolic 'arming' is intended to improve the persistence and efficacy of the lymphocytes as they target various tumor-associated neoantigens in patients with advanced solid tumors.
- Brand names
- Meta10-TILMeta-10-TILMeta 10-TIL
- Other names
- metabolically armed TILsmetabolically reprogrammed tumor-infiltrating lymphocytes
02
Targets
self-pMHC (Self peptide–Major Histocompatibility Complex (MHC))pMHC-II (Peptide-major histocompatibility complex class II complex)
Beyond the preview
Go deeper on metabolically armed tumor-infiltrating lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metabolically armed tumor-infiltrating lymphocytes.